Author:
Toback Seth,Marchese Anthony M.,Warren Brandy,Ayman Sondos,Zarkovic Senka,ElTantawy Islam,Mallory Raburn M.,Rousculp Matthew,Almarzooqi Fahed,Piechowski-Jozwiak Bartlomiej,Bonilla Maria-Fernanda,Bakkour Agyad Ebrahim,Hussein Salah Eldin,Al Kaabi Nawal
Reference20 articles.
1. Asian-origin approved COVID-19 vaccines and current status of COVID-19 vaccination program in Asia: a critical analysis;Chakraborty;Vaccines (Basel),2021
2. Abdelhafiz AS, Ali A, Kamel MM, Ahmed EH, Sayed DM, Bakry RM. Sinopharm's BBIBP-CorV vaccine and ChAdOx1 nCoV-19 vaccine are associated with a comparable immune response against SARS-CoV-2. Vaccines (Basel). 2022;10.
3. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial;Munro;Lancet,2021
4. BNT162b2 mRNA COVID-19 vaccine: first approval;Lamb;Drugs,2021
5. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine;Baden;N Engl J Med,2021